Bill
Bill > SB1030
summary
Introduced
02/03/2025
02/03/2025
In Committee
02/04/2025
02/04/2025
Crossed Over
Passed
Dead
Introduced Session
2025 Regular Session
Bill Summary
An Act relating to prescription drug pricing; creating the 340B Drug Pricing Nondiscrimination Act; providing short title; defining terms; prohibiting certain reimbursement rates; prohibiting certain terms or conditions on a 340B entity; prohibiting certain interference on certain patient choice; prohibiting certain provisions in certain contracts; requiring submission of certain cost data; providing certain exceptions; prohibiting manufacturers or distributors from limiting certain drug actions; prohibiting certain contracts; providing for promulgation of rules; establishing certain fines or fees; providing certain exceptions; amending 36 O.S. 2021, Sections 6960 and 6962, as last amended by Sections 1 and 2, Chapter 306, O.S.L. 2024 (36 O.S. Supp. 2024, Sections 6960 and 6962), which relate to definitions and compliance review; defining terms; prohibiting certain provider requirements; prohibiting certain billing modifier; prohibiting certain modifications; prohibiting certain provider exclusions; prohibiting participation in certain networks; prohibiting basing certain decisions on certain drug pricing; eliminating certain contracting; amending Section 3, Chapter 38, O.S.L. 2022, as last amended by Section 4, Chapter 306, O.S.L. 2024 (36 O.S. Supp. 2024, Section 6966.1), which relates to violations; establishing certain finality of certain claims; providing for codification; and providing an effective date.
AI Summary
This bill establishes the 340B Drug Pricing Nondiscrimination Act, which aims to protect entities participating in the federal 340B drug pricing program from discriminatory practices by health insurers, pharmacy benefits managers (PBMs), manufacturers, and distributors. The legislation defines key terms like "340B drug" and "340B entity," which refer to drugs and organizations participating in a federal program that provides reduced-price pharmaceuticals to certain healthcare providers. The bill prohibits various discriminatory practices, such as reimposing lower reimbursement rates on 340B entities, imposing different contract terms, interfering with patient choice of pharmacy, or requiring additional documentation for 340B drugs. It also prevents manufacturers and distributors from limiting access to 340B drug pricing and establishes potential civil fines between $100 and $10,000 for violations. The Attorney General is granted authority to enforce the provisions, and the law includes safeguards to ensure compliance does not conflict with federal regulations. The bill amends existing Oklahoma statutes to incorporate these new protections and will become effective on November 1, 2025, with the goal of ensuring fair treatment for healthcare providers participating in the 340B drug pricing program.
Committee Categories
Business and Industry
Sponsors (3)
Last Action
Coauthored by Representative Deck (on 03/05/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...